LCTX News & Events

Reports Q4 revenue $6.6M vs $2.9M last year. "2025 was a very productive year for the Lineage team," stated Brian M. Culley, Lineage CEO. "Our mission is to pioneer the emerging field of allogeneic cell therapy outside of oncology by applying our proprietary cell manufacturing technology platform, AlloSCOPE, to the production and transplantation of differentiated cell types, which are intended to replace the cells which a patient has lost, or lost function of, due to various conditions."

Lineage Cell Therapeutics announced the receipt of an induced pluripotent stem cell line containing hypoimmunity edits, from Factor Bioscience. Generation of the line marks a milestone in the strategic collaboration between the two companies, under which Factor developed a proprietary, genetically engineered iPSC line that Lineage can utilize for differentiation into certain cell transplant product candidates. The novel cell line contains edits which are expected to support non-immune privileged and/or non-human leukocyte antigen matched indications and includes an additional disease-specific edit with the potential to further differentiate this cell line from other cell therapies. Acceptance of the line triggered a success payment from Lineage to Factor as reimbursement for Factor's development efforts to date. Factor remains eligible for an additional payment from Lineage subject to Lineage's entry into an exclusive license to utilize the line. Lineage's decision to proceed with the program will be based on further performance criteria and the outcome of additional testing, including the evaluation of the line for its ability to adapt to Lineage's proprietary cell expansion manufacturing platform, the AlloSCOPE platform.

According to a regulatory filing, as previously reported, in December 2021, Lineage Cell Therapeutics (LCTX) entered into a collaboration and license agreement with Genentech, Inc. and Roche (RHHBY) under which Lineage's lead cell therapy program known as OpRegen is being developed for the treatment of ocular disorders, including geographic atrophy secondary to age-related macular degeneration. OpRegen is currently being evaluated in a Phase 2a multicenter clinical trial, known as "GAlette," in patients with GA secondary to AMD. On November 20, 2025, the first development milestone under the Roche Agreement was achieved based on manufacturing and clinical advancements related to the OpRegen cell therapy program. This event triggered a $5M milestone payment to Lineage, which is expected to be received by us within 30 days. As previously reported, approximately 24.1% and 21.5% of the milestone payment will be paid to the Israel Innovation Authority and to Hadasit Medical Research and Development, respectively, in accordance with the Israeli Encouragement of Research, Development and Industrial Initiative Technology Law, 5744-1984, as amended, and in accordance with agreements between Lineage's subsidiary, Cell Cure Neuroscience Ltd., and Hadasit, respectively.